Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI106072

Determination of triiodothyronine concentration in human serum

Kenneth Sterling, Diego Bellabarba, Edward S. Newman, and Milton A. Brenner

Protein Research Laboratory, Bronx Veterans Administration Hospital, Bronx, New York 10468

Department of Pathology, Columbia University College of Physicians and Surgeons, New York 10032

Find articles by Sterling, K. in: PubMed | Google Scholar

Protein Research Laboratory, Bronx Veterans Administration Hospital, Bronx, New York 10468

Department of Pathology, Columbia University College of Physicians and Surgeons, New York 10032

Find articles by Bellabarba, D. in: PubMed | Google Scholar

Protein Research Laboratory, Bronx Veterans Administration Hospital, Bronx, New York 10468

Department of Pathology, Columbia University College of Physicians and Surgeons, New York 10032

Find articles by Newman, E. in: PubMed | Google Scholar

Protein Research Laboratory, Bronx Veterans Administration Hospital, Bronx, New York 10468

Department of Pathology, Columbia University College of Physicians and Surgeons, New York 10032

Find articles by Brenner, M. in: PubMed | Google Scholar

Published June 1, 1969 - More info

Published in Volume 48, Issue 6 on June 1, 1969
J Clin Invest. 1969;48(6):1150–1158. https://doi.org/10.1172/JCI106072.
© 1969 The American Society for Clinical Investigation
Published June 1, 1969 - Version history
View PDF
Abstract

A simplified method has been described for the measurement of triiodothyronine (T3) in human serum. The sensitivity was sufficient for determinations on hypothyroid as well as normal and thyrotoxic sera. The values obtained have been in reasonable agreement with a double isotope derivative assay.

The normal T3 concentration in human serum approximates 0.2 μg/100 ml; the mean ±SD of 31 normal sera was 220 ±27 ng/100 ml. Elevations were observed in sera from 40 patients with thyrotoxicosis (752 ±282 ng/100 ml), and diminutions were found in sera from 10 hypothyroid patients (98±48 ng/100 ml).

In rare instances thyrotoxicosis may be due to elevated serum T3 with normal thyroxine (T4) concentration. The incidence of this condition remains to be determined.

In approximately half the cases with low serum T4 after 131I therapy, the eumetabolic state may be maintained by normal or elevated T3 concentration.

From these data and kinetic studies indicating a rapid turnover it may be inferred that T3 rather than T4 may be the more important hormone in health and in disease.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1150
page 1150
icon of scanned page 1151
page 1151
icon of scanned page 1152
page 1152
icon of scanned page 1153
page 1153
icon of scanned page 1154
page 1154
icon of scanned page 1155
page 1155
icon of scanned page 1156
page 1156
icon of scanned page 1157
page 1157
icon of scanned page 1158
page 1158
Version history
  • Version 1 (June 1, 1969): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts